Topic: non-small cell lung cancer
In February, BMS tallied a lung cancer win for its immuno-oncology combo. But one question remained: Was the win big enough to keep it competitive?
Merck has put up some monster Keytruda-chemo combo numbers that'll raise the bar for rivals looking to steal the class crown.
With both Merck and Bristol-Myers Squibb rolling out closely watched data this weekend, one analyst has already tapped Merck as the early winner.
Merck’s Keytruda already has the immuno-oncology lead in non-small cell lung cancer, and it’s making sure it stays that way.
Barclays analysts checked in on each of their stocks and adjusted their ratings and price targets. The results? A bump-up for Merck and a ding for Pfizer.
Thanks to some new data, Roche has a chance to differentiate itself in the immuno-oncology market for lung cancer. Can it translate into significant sales?
Backed by convincing survival data, AZ’s fifth-to-market immunotherapy Imfinzi just won a breakout FDA approval in certain lung cancer patients.
Pfizer and Merck KGaA have suffered another setback with immuno-oncology med Bavencio—and this one’s raising some eyebrows.
Pfizer is facing tough competition with Xalkori, and the latest move from England’s cost watchdogs isn’t making things any easier.
If you thought 2017 was a game-changer for immuno-oncology, just wait.